Premium
A pilot study comparing low‐dose liposomal amphotericin B with N ‐methyl glucamine for the treatment of American cutaneous leishmaniasis
Author(s) -
Motta J.O.C.,
Sampaio R.N.R.
Publication year - 2012
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2011.04070.x
Subject(s) - medicine , cutaneous leishmaniasis , amphotericin b , leishmaniasis , leishmania , drug , clinical trial , meglumine antimoniate , pharmacology , dermatology , antifungal , immunology , parasite hosting , world wide web , computer science
Background Cutaneous leishmaniasis is an infectious re‐emerging disease that has increased in incidence worldwide. Antimony, a highly toxic drug, remains the first choice therapy to treat it. Liposomal amphotericin B is active against Leishmania and is less toxic than antimony. Objective To compare low‐dose liposomal amphotericin B with N ‐methyl glucamine for the treatment of American cutaneous leishmaniasis. Patients/Methods In a controlled open‐label trial 35 patients with a localized form of American cutaneous leishmaniasis were included. They were allocated to a first group treated with 1.5 mg/kg/day of liposomal amphotericin B for 5 days, or to a second one treated with 20 mgSbV/kg/day of N ‐methyl glucamine for 20 days. Results In the first group, 50% and 81% of patients experienced a clinical cure and clinical improvement respectively. There was a 100% clinical cure in the second group. Conclusion Liposomal amphotericin B seems to be promising and safe for the treatment of American cutaneous leishmaniasis.